Accessibility Menu
 
Quince Therapeutics logo

Quince Therapeutics

(NASDAQ) QNCX

Current Price$0.09
Market Cap$4.88M
Since IPO (2019)-100%
5 Year-100%
1 Year-94%
1 Month-34%

Quince Therapeutics Financials at a Glance

Market Cap

$4.88M

Revenue (TTM)

$0.00

Net Income (TTM)

$56.98M

EPS (TTM)

$-1.22

P/E Ratio

-0.07

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$0.09

Volume

53,233

Open

$0.09

Previous Close

$0.09

Daily Range

$0.08 - $0.10

52-Week Range

$0.08 - $4.55

QNCX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quince Therapeutics

Industry

Biotechnology

Employees

36

CEO

Dirk Thye, MD

Headquarters

South San Francisco, CA 94080, US

QNCX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-248%

Return on Capital

-55%

Return on Assets

-52%

Earnings Yield

-14.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.88M

Shares Outstanding

55.68M

Volume

53.23K

Short Interest

0.00%

Avg. Volume

65.34M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$57.28M

EBITDA

$35.98M

Operating Cash Flow

$31.90M

Capital Expenditure

$257.00K

Free Cash Flow

$32.16M

Cash & ST Invst.

$40.78M

Total Debt

$14.81M

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$36.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.88M

N/A

Market Cap/Employee

$135.49K

N/A

Employees

36

N/A

Net Income

$13.44M

-144.8%

EBITDA

$13.45M

-59.0%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$8.29M

-74.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$359.00K

-97.7%

Short Term Debt

$17.63M

+17359.4%

Return on Assets

-51.85%

N/A

Return on Invested Capital

-55.13%

N/A

Free Cash Flow

$10.00M

-36.9%

Operating Cash Flow

$9.93M

-36.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GUTSFractyl Health, Inc. Common Stock
$0.45-5.20%
MGXMetagenomi, Inc. Common Stock
$1.32-5.04%
IFRXInflaRx N.V.
$0.91-1.95%
ATYRaTyr Pharma, Inc.
$0.75-5.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About QNCX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.